Meloxicam Cyclodextrin Composition for Faster Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used in its conventional form, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows the onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to solubilize meloxicam. The cyclodextrin molecules form inclusion complexes with meloxicam, where the hydrophobic interior of the cyclodextrin ring accommodates the meloxicam molecule while the hydrophilic exterior interacts with aqueous media, thereby enhancing solubility and bioavailability without altering the pharmacological activity of meloxicam
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This changes the solubility parameter of meloxicam from poor to improved, and accelerates the dissolution rate, thereby speeding up the onset of action while maintaining the same therapeutic effect
2Reliability
If the dosage form includes multiple components (meloxicam complex, bicarbonate, rizatriptan), then it provides rapid and sustained pain relief, but the formulation complexity increases
Solution Approach 1:
The patent combines multiple therapeutic agents (meloxicam in cyclodextrin complex, bicarbonate, and rizatriptan) into a single integrated dosage form. This merging of components allows for synergistic therapeutic effects while simplifying the administration process for patients, as all components are delivered together in one formulation rather than requiring multiple separate medications
Solution Approach 2:
The dosage form is designed to perform multiple functions simultaneously: the meloxicam-cyclodextrin complex provides enhanced solubility and anti-inflammatory action, the bicarbonate addresses gastrointestinal side effects, and the rizatriptan provides migraine-specific therapy. This multi-functionality in a single formulation improves overall treatment efficacy while maintaining manageable complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Disclosed herein are formulations for an inclusion complex of cyclodextrin and meloxicam with bicarbonate and methods of use thereof
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.